Furosemide (subcutaneous, scPharmaceuticals) vs Furosemide (subcutaneous, SQ Innovation)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: NKCC2 · full Heart Failure pipeline
Furosemide (subcutaneous, scPharmaceuticals) · FUROSCIX
Marketed by scPharmaceuticals and partners
NCT03458325 · Phase 3 · completed
This was a small, open-label, non-randomized single-group study: 25 participants received Furoscix and were compared with propensity-matched historical claims controls rather than a concurrent randomized control. The primary endpoint was 30-day healthcare utilization cost, an economic measure. A single-group study that is not an extension of a prior randomized trial is weak evidence under the rubric.
Reported efficacy
Healthcare Utilization Costs (Day 0 - Day 30): Healthcare Utilization Costs (Day 0 - Day 30): Furoscix Infusor Prospective Treatment — HF-related healthcare costs: 2920.3 US Dollars (Standard Deviation 7073.2); Overall healthcare costs: 7512.3 US Dollars (met)
Result source: NCT03458325
Furosemide (subcutaneous, SQ Innovation) · Lasix ONYU
Marketed by SQ Innovation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06979726 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Furosemide (subcutaneous, scPharmaceuticals) | Furosemide (subcutaneous, SQ Innovation) |
|---|---|---|
| CV death or HF hospitalisation | —Not posted · NCT04533997 | —Not posted · NCT04533997 |
| HF hospitalisation | —Not posted · NCT04533997 | —Not posted · NCT04533997 |
| CV death | —Not posted · NCT04533997 | —Not posted · NCT04533997 |
| KCCQ clinical summary, change | —Not posted · NCT04533997 | —Not posted · NCT04533997 |
CV death or HF hospitalisation
- Furosemide (subcutaneous, scPharmaceuticals)
- —Not posted · NCT04533997
- Furosemide (subcutaneous, SQ Innovation)
- —Not posted · NCT04533997
HF hospitalisation
- Furosemide (subcutaneous, scPharmaceuticals)
- —Not posted · NCT04533997
- Furosemide (subcutaneous, SQ Innovation)
- —Not posted · NCT04533997
CV death
- Furosemide (subcutaneous, scPharmaceuticals)
- —Not posted · NCT04533997
- Furosemide (subcutaneous, SQ Innovation)
- —Not posted · NCT04533997
KCCQ clinical summary, change
- Furosemide (subcutaneous, scPharmaceuticals)
- —Not posted · NCT04533997
- Furosemide (subcutaneous, SQ Innovation)
- —Not posted · NCT04533997
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Furosemide (subcutaneous, SQ Innovation): no structured comparison results are available for Heart Failure.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Furosemide (subcutaneous, scPharmaceuticals): 3 of 4 rows · Furosemide (subcutaneous, SQ Innovation): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Furosemide (subcutaneous, scPharmaceuticals) |
|---|---|
| Dropout rate | 4%a NCT03458325 · Phase 3 · Heart Failure · phase 3 show 4 more results0%<= 11 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence —Subcutaneous Furosemide NCT05528588 · Phase 2 · registry result, not featured evidence 0%≥ 12 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence 2.9% NCT04593823 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03458325 · Phase 3 · Heart Failure · phase 3 show 4 more results—<= 11 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence —Subcutaneous Furosemide NCT05528588 · Phase 2 · registry result, not featured evidence —≥ 12 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence — NCT04593823 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 25%a NCT03458325 · Phase 3 · Heart Failure · phase 3 show 4 more results—<= 11 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence 28.6%Subcutaneous Furosemide NCT05528588 · Phase 2 · registry result, not featured evidence —≥ 12 BAN-ADHF, Furoscix NCT05528588 · Phase 2 · registry result, not featured evidence 35.3% NCT04593823 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a infusion site bruising 29.2% infusion site pain 29.2% dizziness 12.5% NCT03458325 · Phase 3 · Heart Failure · phase 3 show 2 more resultsincrease in creatinine > 0.3 from discharge to end-of-study visit blood test 14.3% potassium ≤ 3.0 2.9% NCT05528588 · Phase 2 · registry result, not featured evidence hypokalaemia 20.6% infusion site pain 14.7% renal impairment 14.7% NCT04593823 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Furosemide (subcutaneous, scPharmaceuticals)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furosemide (subcutaneous, scPharmaceuticals)'s landscape · Furosemide (subcutaneous, SQ Innovation)'s landscape